Obstetrics & gynecology science

Korean Society of Obstetrics and Gynecology (대한산부인과학회)
권호 표지

The expression and interaction of HLA-G and IL-10 in cervical cancer

자궁경부암에서 HLA-G와 IL-10의 발현 및 상호작용

Kim, Young-Tae;Yoon, Bo-Sung;Kim, Jae-Wook;Kim, Sung-Hoon;Kim, Jae-Hoon;Kim, Sang-Wun;Nam, Eun-Ji
김영태;윤보성;김재욱;김성훈;김재훈;김상운;남은지

  • Published : 20070100
⟨ Previous Next ⟩

Abstract

=목적: 본 연구의 목적은 자궁경부암 환자의 조직에서 HLA-G 유전자 및 IL-10 유전자의 발현을 reverse transcriptase- polymerase chain reaction (RT-PCR) 및 western blot analysis를 통해 알아보고, HLA-G와 IL-10 발현의 상관성과 자궁경부암의 임상병리학적 예후인자와의 연관성을 알아보는 것이다.연구 방법: 2004년 10월부터 2005년 10월까지 자궁경부암으로 진단받은 40명의 환자와 정상환자 15명의 자궁경부 조직을 대상으로 하였다. HLA-G의 mRNA의 측정은 quantitative real time RT-PCR을 이용하였고, IL-10 mRNA의 경우에는 semi-quantitative RT-PCR을 이용하였다. 그리고 HLA-G 및 IL-10의 단백질 발현은 western blot analysis를 통해 측정하였다. 결과: HLA-G 및 IL-10의 mRNA 발현은 정상 자궁경부 조직에 비해 자궁경부암 환자의 조직에서 통계학적으로 유의하게 더 높게 나타났다 (P<0.001, P<0.001). HLA-G와 IL-10의 단백질 발현 또한 자궁경부암 조직에서 더 높은 발현을 보였다 (P<0.001, P=0.041). HLA-G의 mRNA 발현은 IL-10의 mRNA 발현과의 상관성은 통계학적으로 유의하지 않았지만, 상관성 경향을 보였다 (P=0.061). 자궁경부암의 임상병리학적 예후인자와의 연관성에서 HLA-G의 mRNA 발현은 FIGO 병기와 연관성이 있었으며, 초기 병기에서 HLA-G mRNA 발현 수치가 더 높게 나타났다 (P=0.045)

Keywords

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-6 https://doi.org/10.1002/ijc.1440
  2. 한국 부인암 등록 사업 조사 보고서 (2003.1.1-2003.12.31). 대한산부회지 2006; 49: 762-812
  3. Frazer IH. Immunology of papillomavirus infection. Curr Opin Immunol 1996; 8: 484-91 https://doi.org/10.1016/S0952-7915(96)80035-5
  4. Roh J, Kim M, Kim J, Park N, Song Y, Kang S, et al. Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. Cancer lett 2001; 165: 59-62 https://doi.org/10.1016/S0304-3835(01)00401-3
  5. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat Immunol 2002; 3: 999-1005 https://doi.org/10.1038/ni1102-999
  6. Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunother 2001; 24: 392-407 https://doi.org/10.1097/00002371-200109000-00002
  7. Carosella ED, Paul P, Moreau P, Rouas-Freiss N. HLA-G and HLA-E: fundamental and pathophysiological aspects. Immunol Today 2000; 21: 532-4 https://doi.org/10.1016/S0167-5699(00)01707-2
  8. Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 1998; 95: 4510-5 https://doi.org/10.1073/pnas.95.8.4510
  9. Rouas-Freiss N, Marchal RE, Kirszenbaum M, Dausset J, Carosella ED. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc Natl Acad Sci USA 1997; 94: 5249-54
  10. Allan DS, Colonna M, Lanier LL, Churakova TD, Abrams JS, Ellis SA, et al. Tetrameric complexes of human histocompatibility leukocyte antigen (HLA)-G bind to peripheral blood myelomonocytic cells. J Exp Med 1999; 189: 1149-56 https://doi.org/10.1084/jem.189.7.1149
  11. Ibrahim EC, Guerra N, Lacombe MJ, Angevin E, Chouaib S, Carosella ED, et al. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res 2001; 61: 6838-45
  12. Urosevic M, Kurrer MO, Kamarashev J, Mueller B, Weder W, Burg G, et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 2001; 159: 817-24 https://doi.org/10.1016/S0002-9440(10)61756-7
  13. 홍원기, 김영태, 윤보성, 김상운, 김성훈, 김재훈 등. 난소암 조 직에서 HLA-G유전자 발현과 예후 인자와의 상관성. 대한산부회지 2005; 48: 2910-8
  14. Ibrahim eC, Aractingi S, Allory Y, Borrini F, Dupuy A, Duvillard P, et al. Analysis of HLA antigen expression in benign and malignant melanocytic lesions reveals that upregulation of HLA-G expression correlates with malignant transformation, high inflammatory infiltration and HLA-A1 genotype. Int J Cancer 2004; 108: 243-50 https://doi.org/10.1002/ijc.11456
  15. Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997; 71: 630-7 https://doi.org/10.1002/(SICI)1097-0215(19970516)71:4<630::AID-IJC20>3.0.CO;2-E
  16. Roth I, Corry DB, Locksley RM, Abrams JS, Litton MJ, Fisher SJ. Human placental cytotrophoblasts produce the immunosuppressive cytokine interleukin 10. J Exp Med 1996; 184: 539-48 https://doi.org/10.1084/jem.184.2.539
  17. Moreau P, Adrian-Cabestre F, Menier C, Guiard V, Gourand L, Dausset J, et al. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol 1999; 11: 803-11 https://doi.org/10.1093/intimm/11.5.803
  18. Urosevic M, Willers J, Mueller B, Kempf W, Burg G, Dummer R. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 2002; 99: 609-17 https://doi.org/10.1182/blood.V99.2.609
  19. Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Dausset J, Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol 2003; 81: 199-252 https://doi.org/10.1016/S0065-2776(03)81006-4
  20. Lefebvre S, Antoine M, Uzan S, McMaster M, Dausset J, Carosella ED, et al. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 2002; 196: 266-74 https://doi.org/10.1002/path.1039
  21. Singer G, Rebmann V, Chen YC, Liu HT, Ali SZ, Reinsberg J, et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 2003; 9: 4460-4
  22. Paul P, Cabestr Fa, Le Gal FA, Khalil-Daher I, Le Danff C, Schmid M, et al. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res 1999; 59: 1954-60
  23. Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res 2005; 65: 10139-44 https://doi.org/10.1158/0008-5472.CAN-05-0097
  24. Pisa P, Halapi E, Pisa EK, Gerdin E, Hising C, Bucht A, et al. Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc Natl Acad Sci USA 1992; 89: 7708-12 https://doi.org/10.1073/pnas.89.16.7708
  25. Clerici M, Ferrario E, Trabattoni D, Viviani S, Bonfanti V, Venzon DJ, et al. Multiple defects of T helper cell function in newly diagnosed patients with Hodgkin's disease. Eur J Cancer 1994; 30A: 1464-70
  26. Ishigami S, Natsugoe S, Miyazono F, Nakajo A, Tokuda K, Matsumoto M, et al. HLA-G expression in gastric cancer. Anticancer Res 2006; 26: 2467-72